Impact of probiotics in gestational diabetes

Comparison of probiotic capsules and placebo on fasting blood sugar and metabolic parameters in pregnant woman with gestational diabetes or impaired glucose tolerance test

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110310089N4

Enrollment

100

Registered

2016-02-01

Start date

2015-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus arising in pregnancy

Interventions

Intervention 1: Give to patients a bottle contains 30 capsules of probiotics with brand Lactofem from Zist takhmir company that is for a month. Capsules should be taken daily. Intervention 2: Give to

Treatment - Drugs

Give to patients a bottle contains 30 capsules of probiotics with brand Lactofem from Zist takhmir company that is for a month. Capsules should be taken daily.

Give to patients a bottle contains 30 capsules of placebo with from Zist takhmir company that is for a month. Capsules should be taken daily.

Eligibility

Sex/Gender

Female

Age

18 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusions criteria: single pregnancy; new diagnosis of IGT or GDM in the current pregnancy; <34 weeks’ gestation; without insulin or metformin therapy. Exclusions criteria: pregestational diabetes; fetal anomaly; without follow; do not use of probiotics

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Probiotics user. Timepoint: Baseline. Method of measurement: use probiotic capsule.;Placebo user. Timepoint: baseline. Method of measurement: use placebo capsule.	—

Secondary

Measure	Time frame
Fasing blood glocose. Timepoint: Baselie and 4 weeks after intervention. Method of measurement: Blood sample.;Triglyceride. Timepoint: Baselie and 4 weeks after interventin. Method of measurement: Blood sample.;Total cholestrol. Timepoint: Baseline and 4 weeks after intervention. Method of measurement: Blood sample.;Low density lipoprotein(LDL). Timepoint: Baseline and 4 weeks after intrevention. Method of measurement: Blood sample.;High density lipoprotein. Timepoint: Baseline and 4 weeks after intervention. Method of measurement: Blood sample.;Blood pressure. Timepoint: Baseline and 4 weeks aftr intervention. Method of measurement: With manometer in standard position.	—

Measure

Time frame

Fasing blood glocose. Timepoint: Baselie and 4 weeks after intervention. Method of measurement: Blood sample.;Triglyceride. Timepoint: Baselie and 4 weeks after interventin. Method of measurement: Blood sample.;Total cholestrol. Timepoint: Baseline and 4 weeks after intervention. Method of measurement: Blood sample.;Low density lipoprotein(LDL). Timepoint: Baseline and 4 weeks after intrevention. Method of measurement: Blood sample.;High density lipoprotein. Timepoint: Baseline and 4 weeks after intervention. Method of measurement: Blood sample.;Blood pressure. Timepoint: Baseline and 4 weeks aftr intervention. Method of measurement: With manometer in standard position.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Fani

Alzahra hospital

arezoo.fani@yahoo.com+98 13 3375 2660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026